Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $2.8 million for the fourth quarter, which includes non-cash charges of about $1 million, reconciling to a non-GAAP loss of $942,000 [31][32] - The cash burn rate for the fourth quarter was $1.5 million, reflecting operating costs and development costs associated with the implantable device [24] - The equity method investment balance at year-end was $34 million, showing an $8.5 million year-over-year increase consistent with a 33% increase in Lucid stock during 2025 [24][25] Business Line Data and Key Metrics Changes - Lucid reported fourth quarter 2025 EsoGuard revenue of approximately $1.5 million, with a test volume of 3,664 EsoGuard tests, marking a 29% increase in volume and a 24% increase in revenue from the previous quarter [9] - Veris is advancing a cancer care platform and has completed full Epic integration with Ohio State University, receiving positive feedback from clinicians [11][12] Market Data and Key Metrics Changes - Lucid was awarded a U.S. Department of Veterans Affairs contract for EsoGuard, expanding access to a large healthcare system and targeting 9 million enrolled veterans at high risk for gastroesophageal cancer [10] - The company is positioned to leverage its new capital structure to benefit from Lucid's upcoming major value inflection points [5][6] Company Strategy and Development Direction - The company aims to operate as a high-growth, diversified commercial life sciences company with multiple independently financed subsidiaries [5] - A key part of the future plan includes relaunching the MedTech portfolio, with a focus on engaging a new leader for oversight [7][17] - The company is exploring partnerships and opportunities across various medical technologies, including diagnostic and medical devices [64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's improved capital structure and ability to execute its strategic plan, highlighting the successful completion of a restructuring and recapitalization [4][21] - The management team emphasized the importance of the upcoming FDA submission for the implantable device and the potential for commercial expansion following its clearance [43][44] Other Important Information - The company has engaged a new Chief Business Officer to oversee the medical device subsidiaries and is actively evaluating inbound inquiries from potential partners [19][66] - The company has licensed new endoscopic imaging technology from Duke University, which is in the early phases of development [18][55] Q&A Session Summary Question: What are the key metrics for the commercial relationship with OSU? - Management indicated a target of a minimum of 1,000 patients within the first year and a structured plan for rolling out the platform across various departments [39][40] Question: Are the new risk stratification tools part of the contract with OSU? - Management clarified that the development of AI-based tools requires extensive data and discussions with OSU are ongoing regarding their integration [48][50] Question: What is the status of the imaging technology licensed from Duke? - Management noted that the technology is still in early phases, with modifications needed before commercial rollout, and emphasized its potential to transform esophageal pre-cancer management [55][58]

Lucid Diagnostics - EsoGuard revenue reached $1.2 million in Q3 2025, with a test volume of 2,841[9] - A MolDX Contractor Advisory Committee (CAC) meeting unanimously endorsed Medicare coverage for EsoGuard[9] - The company strengthened its balance sheet by netting approximately $27 million in proceeds from an underwritten public offering of common stock[9] Veris Health - Veris Health launched the commercial phase of its strategic partnership with OSU[11] - The company relaunched implantable physiological monitor development, targeting a 2026 FDA 510(k) submission[11] Financial Performance - The company's cash reserves were $3.103 million in 3Q25, a decrease of $901 thousand from $4.004 million in 2Q25[16] - Equity method investments in Lucid were valued at $31.615 million in 3Q25, down $4.383 million from $35.998 million in 2Q25[16] - Revenue plus management fee income was $3.155 million in 3Q25, a decrease of $991 thousand compared to $4.146 million in 3Q24[18] - The company reported a net loss of $6.011 million in 3Q25, a significant change from a net income of $60.711 million in 3Q24[18] - Non-GAAP adjusted loss was $(446) thousand in 3Q25, compared to $(5,439) thousand in 3Q24[18] - Shares outstanding increased to 23.1 million in 3Q25 from 20.1 million in 2Q25[16]